Our results demonstrated that blockage of all the class I PI3K catalytic isoforms exerted a greater anti-cancer effect compared to dual p110γ/δ inhibition, as exemplified by the lower IC50 attained in all the cell lines, whereas isoform-selective inhibition produced negligible effects. Here, PIK3CG is linked to cancer.